Legend Biotech (LEGN) Expected to Post Quarterly Earnings on Tuesday

Legend Biotech (NASDAQ:LEGN) is expected to be releasing its Q3 2026 results before the market opens on Tuesday, November 10th. Analysts expect Legend Biotech to announce earnings of $0.01 per share and revenue of $361.46 million for the quarter. Investors are encouraged to explore the company’s upcoming Q3 2026 earnings summary page for the latest details on the call scheduled for Tuesday, November 10, 2026 at 8:00 AM ET.

Legend Biotech (NASDAQ:LEGN) last released its quarterly earnings data on Tuesday, August 11th. The company reported $0.09 EPS for the quarter, beating the consensus estimate of $0.07 by $0.02. Legend Biotech had a negative net margin of 7.21% and a negative return on equity of 8.71%. The business had revenue of $387.50 million for the quarter, compared to the consensus estimate of $355.96 million. During the same period in the prior year, the firm earned $0.03 earnings per share. The company’s revenue was up 51.9% compared to the same quarter last year. On average, analysts expect Legend Biotech to post ($0.08) EPS for the current fiscal year and $1.16 EPS for the next fiscal year.

Legend Biotech Stock Performance

LEGN stock traded up $0.29 during midday trading on Tuesday, reaching $21.39. 308,357 shares of the company’s stock traded hands, compared to its average volume of 2,383,198. The firm has a market capitalization of $4.15 billion, a PE ratio of -85.68 and a beta of 0.57. The company has a 50-day moving average price of $19.54 and a two-hundred day moving average price of $22.11. Legend Biotech has a 52 week low of $16.24 and a 52 week high of $37.50.

Insider Activity at Legend Biotech

In other Legend Biotech news, CFO Carlos Santos sold 5,430 shares of the business’s stock in a transaction that occurred on Monday, September 21st. The stock was sold at an average price of $9.14, for a total value of $49,630.20. Following the completion of the sale, the chief financial officer owned 14,246 shares in the company, valued at approximately $130,208.44. The trade was a 27.60% decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. Also, Director Corazon (Corsee) D. Sanders sold 27,370 shares of the stock in a transaction that occurred on Tuesday, September 29th. The shares were sold at an average price of $9.46, for a total value of $258,920.20. Following the sale, the director directly owned 52,731 shares of the company’s stock, valued at approximately $498,835.26. This trade represents a 34.17% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. 0.02% of the stock is owned by company insiders.

Wall Street Analysts Forecast Growth

Several brokerages recently commented on LEGN. Weiss Ratings cut shares of Legend Biotech from a “sell (d-)” rating to a “sell (e+)” rating in a research note on Monday, October 19th. Morgan Stanley set a $65.00 price target on shares of Legend Biotech in a report on Friday, September 4th. HC Wainwright reaffirmed a “buy” rating on shares of Legend Biotech in a report on Friday. Royal Bank Of Canada dropped their price target on Legend Biotech from $58.00 to $56.00 and set an “outperform” rating for the company in a research report on Thursday, October 8th. Finally, Oppenheimer cut shares of Legend Biotech from an “outperform” rating to a “market perform” rating and decreased their price objective for the stock from $75.00 to $40.00 in a research report on Wednesday, August 12th. Nine analysts have rated the stock with a Buy rating, five have assigned a Hold rating and one has given a Sell rating to the stock. According to data from MarketBeat, the company currently has a consensus rating of “Moderate Buy” and an average target price of $54.69.

Legend Biotech Company Profile

Legend Biotech Corporation (NASDAQ: LEGN) is a biotechnology company focused on developing, manufacturing and commercializing cell therapies for cancer and other serious diseases. The company’s primary technology is chimeric antigen receptor T-cell (CAR-T) therapy, which genetically modifies a patient’s immune cells to recognize and attack cancer cells.

Legend Biotech’s leading product is CARVYKTI (ciltacabtagene autoleucel), a BCMA-directed CAR-T therapy for certain adults with relapsed or refractory multiple myeloma.